Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

NEW ISSUE: Neopharmed Gentili EUR425m 7NC1 Sr Sec FRN, IPT High 3s

HYC European Market: Deal Flow - General

Ticker

Security

Size

TERM

IPT

NEGENT

Senior Secured Floating Rate Notes due 2033

EUR425m

7NC1

High 3s, par


  • Price Progression:
    • IPT: High 3s, par
  • Issuer: Neopharmed Gentili S.p.A.
  • Ticker: NEGENT
  • Size: EUR425m
  • Format: 144A/Reg S; No Reg Rights
  • Security: Senior Secured FRN due 2033 (7y)
  • Expected Corporate Ratings (M/S/F): B3 (positive) / B (stable) / B (stable)
  • Expected Issue Ratings (M/S/F): B3 / B / B
  • Optional Redemption: NC1 (par)
  • Day Count: ACT/365
  • Denominations: 100kx1k
  • Listing: Luxembourg Stock Exchange
  • Law: New York
  • Sole Global Coordinator and Physical Bookrunner: BNP Paribas (B&D)
  • Joint Bookrunners: Banca Akros, CACIB, GS, IMI, JPM, Natixis
  • UOP: Refinance existing indebtedness and fund a distribution to parent to repay a portion of the PIK Notes
  • Biz: A leading primary care pharmaceutical company in Italy that promotes a well-established and diversified portfolio of leading branded off-patent products
  • HQ: Milan, Italy

Marketing:

  • Investor Call: GIC 8:30 UKT / 9:30 CET, 16-June-2026
  • Q&A Sessions: 16/17-June-2026

https://dealroadshow.com/e/NEO2026 (Access Code: NEO2026)

https://evercall.co/oacc/46099 (GIC Registration)

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.